key: cord-0886003-ufoai4du
authors: Meyer, Benjamin; Torriani, Giulia; Yerly, Sabine; Mazza, Lena; Calame, Adrien; Arm-Vernez, Isabelle; Zimmer, Gert; Agoritsas, Thomas; Stirnemann, Jérôme; Spechbach, Hervé; Guessous, Idris; Stringhini, Silvia; Pugin, Jérôme; Roux-Lombard, Pascale; Fontao, Lionel; Siegrist, Claire-Anne; Eckerle, Isabella; Vuilleumier, Nicolas; Kaiser, Laurent
title: Validation of a commercially available SARS-CoV-2 serological immunoassay
date: 2020-06-27
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.06.024
sha: 9c0f225a8aec963d8c934387533c8a90e46f9619
doc_id: 886003
cord_uid: ufoai4du

OBJECTIVES: To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA immunoassay for COVID-19. METHODS: In this unmatched (1:2) case-control validation study, we used sera of 181 laboratory-confirmed SARS-CoV-2 cases and 326 controls collected before SARS-CoV-2 emergence. Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-neutralization assay. RESULTS: COVID-19 patients were more likely to be male and older than controls, and 50.3% were hospitalized. ROC curve analyses indicated that IgG and IgA had high diagnostic accuracies with AUCs of 0.990 (95% Confidence Interval [95%CI]: 0.983-0.996) and 0.978 (95%CI: 0.967-0.989), respectively. IgG assays outperformed IgA assays (p=0.01). Taking an assessed 15% inter-assay imprecision into account, an optimized IgG ratio cut-off > 2.5 displayed a 100% specificity (95%CI: 99-100) and a 100% positive predictive value (95%CI: 96-100). A 0.8 cut-off displayed a 94% sensitivity (95%CI: 88-97) and a 97% negative predictive value (95%CI: 95-99). Substituting the upper threshold for the manufacturer’s, improved assay performance, leaving 8.9% of IgG ratios indeterminate between 0.8-2.5. CONCLUSIONS: The Euroimmun assay displays a nearly optimal diagnostic accuracy using IgG against SARS-CoV-2 in patient samples, with no obvious gains from IgA serology. The optimized cut-offs are fit for rule-in and rule-out purposes, allowing determination of whether individuals in our study population have been exposed to SARS-CoV-2 or not. IgG serology should however not be considered as a surrogate of protection at this stage.

Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based 48 recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) 49 analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-50 neutralization assay. 51

Results: COVID-19 patients were more likely to be male and older than controls, and 50.3% 52 were hospitalized. ROC curve analyses indicated that IgG and IgA had high diagnostic 53 accuracies with AUCs of 0.990 (95% Confidence Interval [95%CI]: 0.983-0.996) and 0.978 54 (95%CI: 0.967-0.989), respectively. IgG assays outperformed IgA assays (p=0.01). Taking an 55 assessed 15% inter-assay imprecision into account, an optimized IgG ratio cut-off > 2.5 56 displayed a 100% specificity (95%CI: 99-100) and a 100% positive predictive value (95%CI: 96-57 100). A 0.8 cut-off displayed a 94% sensitivity (95%CI: 88-97) and a 97% negative predictive 58 value (95%CI: 95-99). Substituting the upper threshold for the manufacturer's, improved assay 59 performance, leaving 8.9% of IgG ratios indeterminate between 0.8-2.5. 60

Conclusions: The Euroimmun assay displays a nearly optimal diagnostic accuracy using IgG 61 against SARS-CoV-2 in patient samples, with no obvious gains from IgA serology. The 62 optimized cut-offs are fit for rule-in and rule-out purposes, allowing determination of whether 63 individuals in our study population have been exposed to SARS-CoV-2 or not. IgG serology 64 should however not be considered as a surrogate of protection at this stage. 65

High throughput and reliable serological assays detecting antibodies against SARS-CoV-2 are 67 essential to determine the proportion of SARS-CoV-2 infected individuals and estimate the 68 current seroprevalence in the general population or in high-risk groups, such as health care 69 workers. Serological assays can complement diagnostic strategies focusing on the identification 70 of the infectious agent during the acute phase of disease. Unlike RT-PCR, they can identify 71 infected individuals that remained asymptomatic or undiagnosed, which are both frequent 72 conditions during SARS-CoV-2 infection, long after the initial infection. Validated serological 73 assays are also key to understanding the (immuno)-pathophysiology of COVID-19 in various 74 patients' groups and will be critical to characterize responses elicited by the numerous vaccine 75 candidates in development [1] . 76

Designing serological testing strategies with high sensitivity and specificity and with acceptable 77 positive (PPV) and negative predictive values (NPV) is far from trivial, and requires taking two 78 major analytical aspects into account: analytical specificity and sensitivity [2, 3] . The former may 79 largely be determined by the degree of cross-reactivity with other CoVs, which frequently cause 80 common colds in humans (i.e. HCoV-229E, -NL63, -OC43 and -HKU1) [4] resulting in 81 seroprevalence rates usually above 90% in adults [5] . 82

This cross-reactivity occurs when virus-specific antigenic epitopes are highly similar and 83 recognized by the same B cells. It is best defined by the proportion of "false-positive" SARS-84

CoV-2 results in individuals who were never exposed to this pathogen. In contrast to common 85 cold CoVs, the seroprevalence for MERS-CoV is low even in endemic countries [6] . Therefore, 86 cross-reactivity between MERS-CoV and SARS-CoV-2 is not a critical factor when assessing 87 population seroprevalence. Previous studies have shown that antibodies against common cold 88

CoVs can cause considerable cross-reactivity in serological assays, depending on the type of 89 assay and antigens used. Particularly, whole virus-or nucleocapsid protein-based assays 90 showed a higher cross-reactivity compared to whole spike or S1 domain-based assays resulting 91 in lower specificity [4] . During the early phase of an outbreak, when SARS-CoV-2 92 seroprevalence is low, serological testing strategies must have a very high specificity to reach a 93 high positive predictive value (PPV) and avoid false positive results. 94

On the other hand, analytical sensitivity is strongly influenced by the epidemic course, the 95 disease biology, and numerous analytical factors. All these interrelated items are primarily 96 influenced by the intrinsic immunogenicity of the SARS-CoV-2 antigens and the magnitude and 97 duration of B cell responses elicited by infection, be it asymptomatic, benign, moderate or 98 severe [2,3]. 99

Last but not least in the context of a pandemic, the availability of high throughput and reliable 100 diagnostic platforms is key for health care systems to effectively handle the testing demand, 101 while respecting clinically compatible diagnostic turnaround times (TAT). In this study, we 102 performed an extensive validation of a high throughput SARS-CoV-2 commercial serological 103 platform quantifying both serum IgG and IgA against the S1 protein. As reference method, we 104 used a whole spike-based recombinant immunofluorescence assay (rIFA) [4, 7, 8] . Selected sera 105 from SARS-CoV-2-infected patients were assessed for their neutralization capacity using a 106 pseudovirion assay (see below). 107 108

Aims 110

The aim of this study is to validate and define the operational cut-off values of a commercially 111 available ELISA-based SARS-CoV-2 serological assay that could be applied at large scales to 112 reliably determine the presence of specific IgG as a marker of SARS-CoV-2 infection. This study 113 used RT-PCR confirmed cases, but the goal was to be able to identify exposure to SARS-CoV-2 114 by immunoassay alone. Therefore, the ELISA results were compared against recombinant 115 immunofluorescence assay (rIFA), which was considered as the reference method due to its 116 demonstrated high specificity for serology of other CoVs such as MERS-CoV An in-house developed recombinant immunofluorescence assay (rIFA) using the whole spike 231 protein of SARS-CoV-2 as antigen was used to assess spike-specific serum IgG. Since rIFA 232 was used as a confirmatory assay, we maximized its specificity by interpreting putative 233 negatives as negative to avoid false positive results. Among negative control samples, we found 234 no positive, six putative negative (1.8%) and 320 (98.2%) negative samples indicating a 235 specificity of 100%. Among COVID-19 samples there were 165 (91.2%) positive, two (1.1%) 236 putative negative and 14 (7.7%) negative samples, indicating an overall detection rate of 91.2%. 237

We found that rIFA seropositivity was low at 0-10 dpos/dpd (12.5%) but increased to 92.0% and 238 100% in sera collected at 11-20 and 21-39 dpos/dpd, respectively (table 1) indeterminate and 13 (7.2%) negative samples for IgA. This resulted into an overall significantly 251 higher seropositivity for IgA (90.6%) than IgG (85.1%) in the S1-based ELISA (p= 0.041). 252 253 Next, we analysed the seropositive rates of both ELISAs at different dpos or dpd ( Figure 1E ) 254 according to the EI cut-offs. Sera collected 21 dpos/dpd had a similarly high seropositivity 255 (above ratio 1.1) for both IgG (96.7%) and IgA (96.7%) (p >0.99). A higher seropositivity was 256 observed for IgA compared to IgG for sera collected at 11-20 dpos/dpd (91.1% vs 84.8%, p= 257 0.0264) but not 0-10 dpos/dpd (37.5% vs 0%, p= 0.2). No significant difference was found 258 between hospitalized and outpatients in IgG or IgA ELISA (p= 0.833, and p= 1.000, 259 respectively). 260 261 ROC curve analysis (Fig 1; C and D IgG ratio cut-off of 2.5 (2.1 + 0.42) would be the lowest able to secure 100% PPV while taking 291 into account the analytical imprecision. Furthermore, an LSC of 0.42 also indicates that the 292 indeterminate zone proposed by the manufacturer (between 0.8 and 1.1) should be 293 reconsidered, as it falls within the analytical imprecision range. At the 2.5 IgG ratio cut-off, ROC 294 curve analyses indicated that the SE was 73%, the SP 100%, and the NPV 89%. Thus, 295 selecting a 2.5 cut-off, rather than the recommended 1.1 cut-off for IgG seropositivity, allows the 296 securing of a PPV of 100% despite a 15% imprecision. Higher VCs would translate into a higher 297 seropositivity cut-off to secure an identical PPV. For rule-out purposes (i.e. the seronegativity 298 lower cut-off), the best trade-off IgG ratio cut-off was found to be < 0.8. At this value, the SE 299 was 94%, the SP 97%, the NPV 97% and the PPV 97% (table 3) . This defines an indeterminate 300 range between IgG ratios of 0.8 and 2.5, which represented 45 cases (8.9%) of our samples 301 (including 12 control and 33 COVID-19 samples). In this indeterminate zone, all 12 sera from 302 controls were confirmed as negative (n=11) or putative negative (n=1) by rIFA. For 303 indeterminate samples of COVID-19 patients, all 33 were positive by rIFA. 304

In the subgroup of patients whose samples were taken before 21 dpos, using the manufacturer 305

IgG ratio seropositivity cut-off (1.1), the SE was 89%, the SP 100%, the PPV 100%, and the 306 NPV 59%. At the manufacturer seronegative cut-off (<0.8), the SE was 91%, the SP 100%, the 307 PPV 100%, and the NPV 64% (table 3) . Importantly, no patient displayed a ratio between 0.8 308 and 1.1 in this subgroup, preventing us from estimating the importance of the indeterminate 309 cases. 310

Using the aforementioned optimized IgG ratio cut-off for IgG seropositivity (2.5), the SE was 311 69%, the SP 100%, the PPV 100%, and the NPV 33%. At the cut-off for IgG seronegativity 312 (<0.8), the SE was 91%, the SP 100%, the PPV 100%, and the NPV 64% (table 3) . The number 313 of undetermined cases between 0.8 and 2.5 IgG ratio values represented 27.5% (33/120) of the 314 subgroup. Taken together, these results indicate that if the seropositivity cut-off of 2.5 for the 315 IgG ratio would be suitable for patients with sample taken <21 days post symptoms onset, the 316 seronegative cut-off of 0.8 would display a non-optimal NPV for rule-out purposes. The optimal 317 seronegative (NPV 100%) cut-off would have been <0.4, at the cost of a modest increase of 318 indeterminate cases to 31% (37/120). Thus, this assay performs best for convalescent samples 319 taken as of 21 dpos. 320 321

The key finding of this validation study, derived from a large cohort of laboratory-confirmed 323 SARS-CoV-2 cases and unmatched negative controls, is that the present CE-IVD marked 324 immunoassay for IgG has a good diagnostic accuracy with an AUC of 0.99 and outperformed 325

IgA according to ROC curve comparisons. These results parallel the ones obtained by two other 326 smaller studies [8, 17] , which tested the non CE-marked ELISA version and showed potentially 327 better diagnostic performances of IgG compared to IgA ELISA but lower AUCs compared to this 328 study. Our improved results might result from the higher number of negative controls and 329

COVID-19 patient sera tested, and from the decreased non-specific background relative to that 330 observed in the earlier studies. Compared to the Wantai total Ig ELISA and Diasorin Liason 331 assay the Euroimmun IgG ELISA has a similar specificity. Also the sensitivity for samples taken 332 >14dpos was comparable between all three assay, for sample taken before 14dpos the 333 sensitivity of the Euroimmun assay was lower than for the Wantai assay but a higher than for 334 the Diasorin assay [18] . 335

Despite the greater performance of the Euroimmun IgG based ELISA, it was reassuring to see 336 that the IgA results correlated well with the IgG results and gave very similar AUCs upon ROC 337 analyses. However, knowing if and how IgA could be used in clinical practice to further refine 338 rule-in our rule-out strategies still remains elusive. Interestingly, despite higher mean IgG ratios 339 in hospitalized patients compared to outpatients, i.e. milder cases, ROC analysis did not reveal 340 a lower performance of the assay for mild cases. As all COVID19 patients in this study 341 displayed at least mild symptoms, it remains to be investigated how the Euroimmun ELISA 342 performs on sera from asymptomatic patients and if the cut-offs need to be adapted for this 343 group of patients. Also, the potential earlier waning of antibodies in asymptomatic/mild cases 344 could potentially influence the performance of immunoassays and should be considered for 345 future seroprevalence studies. 346

The second notable finding of this study is that the current manufacturer cut-offs are prone to 347 misinterpretations and should not be used without proper evaluation before routine testing. 348

Keeping in mind the challenges of developing a serological assay for a new viral disease in an 349 emergency situation; securing both rule-in and rule-out cut-offs is key to mitigate the 350 unavoidable risk of false positive and false negative results due to the combination of a highly 351 dynamic pre-test probability variation, with a suboptimal seroconversion time when studies are 352 undertaken at the peak of an epidemic. Our analyses revealed the following limitations of the 353 manufacturer's seropositivity cut-off. First, with an inter-assay imprecision of 15% assessed at 354 an IgG ratio of 2.09 translating into a LSC of 0.42 IgG ratio, our results indicate that the 355 analytical imprecision is higher than the range of the indeterminate zone proposed by the 356 manufacturer, which encompasses a delta of 0.3 IgG ratio. This implies that any result within the 357 0.8-1.1 IgG ratio range could be randomly either above, within or below these values just 358 because of analytical imprecision. Secondly, with a LSC of 0.42 our results indicated that a 359 higher IgG ratio cut-off value was needed to secure an optimal specificity and PPV. Adding the 360 0.42 LSC to the highest ratio shown by a negative control sample (2.1) yielded a 2.5 ratio as the 361

IgG seropositivity cut-off with a PPV of 100%, the lower end of the 95%CI still being compatible 362 with a 96% rule-in strategy. Notably, using this cut-off in the subgroup of patients under 21 363 dpos/dpd, the SP and PPV were still 100%, however, with broader confidence intervals. The 364 negative predictive value at the rule-out cut-off of 0.8 IgG ratio, as suggested by the 365 manufacturer was in line with an overall NPV of 97%, with a 95% at the lower end of the 95%CI. 366

In the subgroup of patients under 21 dpos/dpd this interval was found to be substantially larger 367 (95%CI: 43-81). Taken together, these results indicate that at this stage the optimal rule-in cut-368 off should be set at ≥2.5 of IgG ratio for seropositivity and at <0.8 of IgG ratio for rule-out 369 purposes (seronegativity). With these optimized "Geneva's" cut-offs, the indeterminate zone 370 represented 8.9% of the cases overall (12 controls and 33 COVID-19 samples), representing a 371 volume easily amenable to further confirmation tests like rIFA. 372

In this respect, the 13 discordant cases between IgG ELISA and rIFA were tested using the 374 pseudo-NT assay. This indicated that all non-positive samples (negative and putative negative) 375 by rIFA were negative in the pseudo-NT assay, and that all positive samples by rIFA (but IgG 376 ELISA negative) were positive in the pseudo-NT assay. One sample that was indeterminate in 377

IgG ELISA and positive in rIFA was also positive in pseudo-NT. These findings may indicate an 378 earlier IgG antibody response, which could better mediate virus neutralization, against the S2 379 domain of the spike protein, as previously suggested for SARS-CoV-1 neutralizing antibodies 380 targeting the S2 domain [19] [20] [21] [22] . Although based upon a limited number of observations which 381 prevents us from drawing final conclusions, these results suggest that rIFA may be an 382 appropriate confirmatory assay in the future. 383

Regarding potential limitations, we need to highlight several additional points. We evaluated an 384 ELISA assay measuring antibodies against the S1 domain of the spike protein and not against 385 the full protein, which may contain other highly relevant epitopes from the S2 domain. Such 386 factors could potentially explain why some samples were negative by ELISAs but positive by 387 rIFA, as the whole-spike protein is used in rIFA. Secondly, we strongly emphasize two important 388 cut-off limitations related to the analytical imprecision. At the level of the analytical imprecision, 389 the SARS-CoV-2 IgG intra-individual biological variation being unknown, we had to use the LSC 390 instead of the reference change value [23] , which most likely would have translated into a higher 391 seropositivity cut-off. Along the same line, because the intra-lot imprecision of the reagents is 392 still undetermined, but expected to be higher than 15%, this could have a similar impact on cut-393 off determination. Nevertheless, these cut-offs implemented in routine testing at the Geneva 394

University Hospitals (GE-cut-offs) proved useful in the management of a number of clinically 395 compatible COVID-19 patients with negative PCR results. 396 Importantly, this study is a diagnostic accuracy validation study and not a seroprevalence study. 397

This implies that the current seropositivity cut-off has to be considered with caution in population 398 studies. Indeed, the 100% PPV achieved in this study was due to combined effect of a 100% 399 specificity and a 2:1 distribution of control and samples form patients with positive SARS-CoV-2 400 PCR. Therefore, in population seroprevalence studies with a lower expected proportion of 401 COVID-19, the PPV at the 2.5 cut-off will likely decrease. In this context, increasing the rule-in 402 necessary. Due to this limitation, at this stage we recommend the confirmation of all positive 404 ELISA results (including ratios above 2.5) using a second serological assay such as rIFA for 405 seroprevalence studies with a low pre-test probability, and the confirmation of doubtful ELISA 406 results in settings with a pre-test probability around 35%. A summary of our proposed testing 407 strategy is given in figure 2 . 408 409

In conclusion, in this validation study performed on 507 sera, of which 35.7% came from 410 patients with COVID-19, we demonstrate a close to optimal diagnostic accuracy of IgG SARS-411

CoV-2 serology of the Euroimmun assay, without any obvious gains from IgA serology. Taking  412 analytical imprecision into account, we propose optimized cut-offs allowing a PPV of 100% and 413 a NPV of 97% to be secured with an indeterminate zone comprising about 8.9% of the results, 414 for which additional rIFA analyses are currently necessary. Ongoing seroprevalence studies will 415 be instrumental to further refine the optimal rule-in and rule-out cut-offs, as well as the optimal 416 testing strategy, which may require a highly specific confirmatory assay. For the time being, this 417 assay seems to be fit for the purpose of enabling authorities to make informed decisions 418 regarding measures to be taken in order to manage the SARS-CoV-2 pandemic. Using the GE 419 cut-offs could also allow the determination of whether individuals have been exposed or not to 420 SARS-CoV-2 with high confidence. As a final caution, at this time simple 2) dpos days post onset of symptoms, dpd days post diagnosis, rIFA recombinant immunofluorescence assay 1: EI cut-offs: <0.8 = negative; ≥0.8 and <1.1 = indeterminate; ≥1.1 = positive 2: GE cut-offs: <0.8 = negative; ≥0.8 and <2.5 = indeterminate; ≥2.5 = positive 

SARS-CoV-2 Vaccines: Status Report

Serological Testing for the Diagnosis of Emerging Infectious Diseases

Dengue and Zika: Control and Antiviral Treatment Strategies

Guidelines of the Office International des Epizooties for laboratory quality evaluation, for 458 international reference standards for antibody assays and for laboratory proficiency testing

Serological assays for emerging coronaviruses: 461 Challenges and pitfalls

Prevalence of antibodies to four human 464 coronaviruses is lower in nasal secretions than in serum

Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, 468 cross-sectional, serological study

Assays for 471 laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus 475 Disease

Detection of 2019 478 novel coronavirus (2019-nCoV) by real-time RT-PCR

The kappa statistic in reliability studies: use, interpretation, and sample 481 size requirements

A vesicular stomatitis virus replicon-based bioassay for the 483 rapid and sensitive determination of multi-species type I interferon

Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion

Vesicular 489 stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike 490 protein

Monitoring skeletal changes by radiological techniques

Long-term variability of bone turnover 494 markers in patients with non-metastatic breast cancer

Comparing the areas under two or more 496 correlated receiver operating characteristic curves: a nonparametric approach

499 Evaluation of nine commercial SARS-CoV-2 immunoassays

502 Towards the next phase: evaluation of serological assays for diagnostics and exposure 503 assessment. Infectious Diseases (except HIV/AIDS)

A human SARS-CoV neutralizing 506 antibody against epitope on S2 protein

B-cell responses in patients 509 who have recovered from severe acute respiratory syndrome target a dominant site in the 510 S2 domain of the surface spike glycoprotein

Amino Acids 1055 to 513 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein 514 Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral 515

Quantitative comparison of 517 the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein 518 in virus neutralization and blocking of receptor binding: implications for the functional roles 519 of S2 subunit

Reference change values: how useful are they? 521

We would like to thank Markus Hoffmann and Stefan Pöhlmann (DPZ, University of Göttingen) 440 for providing a SARS-CoV-2 spike protein expression vector. We thank Erik Boehm for help with 441 writing and editing the manuscript. We are also thankful to Romain Burquier, Krystel Tommasini, 442